que la mortalidad a largo plazo esté relacionada sobre todo con la recidiva de la enfermedad actuaciones en una guía de seguimiento del paciente trasplantado. . documento recoge recomendaciones farmacoterapéuticas, de autocuidado, de . de las guías. • Algunos pacientes pueden comenzar con una diabetes de. Efectividad del seguimiento farmacoterapéutico en diabéticos tipo 2 clínica, se obtuvo información sobre medicamentos antidiabéticos utilizados, dosis, .. Guías ALAD de diagnóstico, control y tratamiento de la diabetes mellitus tipo 2. Objetivos: Realizar un seguimiento farmacoterapéutico y educar a pacientes conocimiento sobre la menopausia y la THR en pacientes menopaúsicas. Keywords: Hormone . ministerial que generará Guías Clínicas y tratará . stock de éste por el laboratorio que los produce. Diabetes. 38%. Depresión.
|Published (Last):||13 April 2010|
|PDF File Size:||10.75 Mb|
|ePub File Size:||3.63 Mb|
|Price:||Free* [*Free Regsitration Required]|
To learn about the gyia of problems related to medications and negative outcomes associated with drugs that can be detected, prevented and solved in patients with chronic kidney disease, through pharmaceutical care practice. Mean age farmacoterspeutico The patients selected were notified by phone for their participation in the study; they were then summoned to be furnished the detais of their participation and to sign an informed consent form once they accepted to participate in the study.
Universidad de Granada Grupo de Investigación en Atención Farmacéutica
Reduction of the therapeutic effects of some drugs such as thiazide diuretics. Though patients were being treated with the medication for their basal disease, this was not gui controlled, and this triggered a higher likelihood of presenting other NOMs, and a higher risk to their health.
Dose readjustments were conducted because treatments were not effective and safe, through pharmaceutical intervention. It was calculated that the among the main antidiabetic medications consumed [Defined Daily Dose DDD ] glibenclamide represented 0. The status of the condition was also elaborated for this group and a final visit was conducted; thereby, detecting the NOM.
The study was conveniently conducted in these cities because there was trained personnel for said purpose.
Finally, it must be stated that the results are only applicable to populations of diabetic patients with similar characteristics who are affiliated to the contributive healthcare regime of Colombia’s General System of Health and Social Security. Barroso A, Moral G.
The most frequent NOM causes in these four pharmacological groups darmacoterapeutico thus: Using the random number table method, we assigned the groups farmacpterapeutico random and stratified manner; in the intervention group, who had pharmacotherapeutic monitoring for 18 months; and in the control group, who were merely interviewed at the beginning and at the end of the study.
The variables were classified as dependent: Many of these difficulties came about because of the lack of support and commitment with the study from personnel in the participating healthcare insurance carriers.
The researchers could not guarantee that the written reports diabetee the intervention recommendations made by a pharmacist reached the treating physician; thus, the suggested intervention would or would not be accepted upon the detection of an NOM.
These findings farmacoterapeugico that the active involvement of Pharmacists in the treatment of farmacotfrapeutico anaemia for patients under hemodialysis had a great therapeutic impact. In developed nations as in developing nations, effectiveness of the therapy measured by controlling HbA1c figures ranges between Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: It was Descriptive, because the characteristics of the variables associated with the PF process were determined in patients with CKD, through the detection, prevention and solution of DRPs and NOMs and pharmaceutical interventions; and regarding time, it was Retrospective.
Within PCP, we must highlight the identification, prevention and solution of Negative Outcomes associated with Medication NOMswhich are considered events that can affect patient health due to the use of medications 9 – 11 ; and all this is caused by the presence of one or more Drug-Related Problems DRPswhich are circumstances or events that lead or can lead to the development of a NOM.
The outcomes of the pharmaceutical interventions in the study were statistically analyzed with the STATA program version Diabetes mellitus; Glucosylated hemoglobin A; Hypoglycemic agents; Pharmaceutical services; Colombia.
The inability by patients to excrete drugs that are eliminated through the kidneys can lead to a build-up or metabolites, in case of repeated administration. Problemas de proceso y resultado relacionados con los medicamentos: Statistical Analysis The outcomes of the pharmaceutical interventions in the study were statistically analyzed with the STATA program version In total, 12 dose re-adjustments were conducted, and 10 of these were accepted.
Universidad de Granada Grupo de Investigación en Atención Farmacéutica [WorldCat Identities]
NOM are classified into problems of necessity, effectiveness, and safety; necessity NOM include untreated health problems and the effects of unnecessary medications, effectiveness NOM include the quantified and non-quantified ineffectiveness, and safety NOM include quantified and non-quantified lack of safety 9 The greatest diabetss of NOM was identified for antidiabetic medications with cases for metformin Sdguimiento and non-parametric hypotheses tests were run for related samples, comparing the initial and final glycated hemoglobin within the same groups.
The status of the condition was elaborated including diagnosis, each of the medications being taken, doses and dose intervals.
The distribution of the different study and sociodemographic variables can be seen diahetes Table 1. Opportunities and responsabilities in the Pharmaceutical Care. All this based on good communication and cooperation between the patient and health personnel 9. It is worth mentioning that in the study carried out, there was an important loss of patients In the future, in case pharmacotherapeutic monitoring is incorporated to daily care of diabetic patients, commitment is needed from healthcare insurance carriers EPS to make available the offices for the interviews, facilitate easier access to clinical records and paraclinical exams, updates of member addresses, generation of settings for meetings and discussion with treating physicians to socialize the NOM findings and the pharmaceutical recommendations, implement recommendations, and evaluate results.